GlassScriptPhysician profile
Jason D Philippe
NPI 1982165775
$2,146.46
in general payments reported to CMS, 2019-2025
16 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.75 · 2023: $746 · 2024: $903 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $414.63 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $362.17 | 2023-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $321.28 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $289.94 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $241.47 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.04 | 2023-2024 | Jardiance |
| Abbott Laboratories | $60.65 | 2023-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $53.66 | 2023-2024 | |
| Idorsia Pharmaceuticals US INC | $49.57 | 2023-2024 | Quviviq |
| Pfizer INC. | $40.85 | 2023-2025 | |
| Exact Sciences Corporation | $40.00 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $32.81 | 2025 | Repatha, Otezla |
| Daiichi Sankyo INC. | $27.12 | 2024 | Injectafer |
| Janssen Pharmaceuticals, INC | $25.00 | 2023 | Xarelto |
| Si-Bone, INC. | $20.11 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $13.16 | 2023 | Contrave, Nexlizet, Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Philippe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.